LncRNA PELATON, a Ferroptosis Suppressor and Prognositic Signature for GBM

Abstract

PELATON is a long noncoding RNA also known as long intergenic nonprotein coding RNA 1272 (LINC01272). The known reports showed that PELATON functions as an onco-lncRNA or a suppressor lncRNA by suppressing miRNA in colorectal cancer, gastric cancer and lung cancer. In this study, we first found that PELATON, as an onco-lncRNA, alleviates the ferroptosis driven by mutant p53 and promotes mutant p53-mediated GBM proliferation. We also first confirmed that PELATON is a new ferroptosis suppressor lncRNA that functions as a ferroptosis inhibitor mainly by mutant P53 mediating the ROS ferroptosis pathway, which inhibits the production of ROS, reduces the levels of divalent iron ions, promotes the expression of SLC7A11, and inhibits the expression of ACSL4 and COX2.PELATON can inhibit the expression of p53 in p53 wild-type GBM cells and regulate the expression of BACH1 and CD44, but it has no effect on p53, BACH1 and CD44 in p53 mutant GBM cells. PELATON and p53 can form a complex through the RNA binding protein EIF4A3. Knockdown of PELATON resulted in smaller mitochondria, increased mitochondrial membrane density, and enhanced sensitivity to ferroptosis inducers to inhibit GBM cell proliferation and invasion. In addition, we established a favourite prognostic model with NCOA4 and PELATON. PELATON is a promising target for the prognosis and treatment of GBM.

Comprehensive Analysis Identifies Ameloblastin-Related Competitive Endogenous RNA as a Prognostic Biomarker for Testicular Germ Cell Tumour

“…Hung et al [76] subsequently verified that it has macrophage and monocyte specificity and can be elevated in levels in unstable atherosclerotic plaques. In recent studies, it was shown to be an iron death suppressor and one of the oncogenes of glioblastoma multiforme (GBM) [77]. Our analysis also demonstrates that PELATON can be an independent prognostic factor for TGCT progression-free interval and is associated with the lymphatic invasion and the first location of TGCT.…”

Identification and validation of a ferroptosis-related lncRNA signature to robustly predict the prognosis, immune microenvironment, and immunotherapy efficiency in patients with clear cell renal cell carcinoma

“…Studies on the other lncRNAs also proved their functions in oncogenesis, especially in the ferroptosis process, such as knockdown of lncRNA PELATON enhanced sensitivity to ferroptosis inducers to inhibit cell proliferation and invasion in glioblastoma cells ( Fu et al, 2022 ); LINC02609 was positively correlated with late stage, grade, and distant metastasis in ccRCC ( Su et al, 2021 ), and associated with OS in soft tissue sarcoma ( He et al, 2017 ), what’s more, other similar research also identified LINC02609 as ferroptosis-related lncRNA in kidney carcinoma ( Han et al, 2022 ; Xing et al, 2021 ; Bai et al, 2022 ; Shu et al, 2021 ). Further research on the these lncRNAs, especially how these lncRNAs participate in the process of ferroptosis, can provide new insights for revealing the mechanism of renal cell carcinoma at the molecular level.With the in-depth study of tumor immunology and molecular biology, immunotherapy provides a new perspective for tumor treatment.…”

Construction of a ferroptosis-related lncRNA signature for predicting prognosis, immune response and drug sensitivity in cervical squamous cell carcinoma and endocervical adenocarcinoma

“…Ferroptosis is an iron-related cell death mechanism that has recently been the subject of fundamental scientific research and has been shown to affect tumor therapy [35][36][37]. Many investigations have revealed that lncRNA is related to tumor ferroptosis, cancer progression, and tumor drug resistance [38][39][40][41]. Therefore, lncRNA is anticipated to be a treatment target and biomarker for CESC.…”